At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Party season approaches; but first, conferences.